Image Credit: Canva
It was a typical morning. My mother was getting ready; this was her usual routine: bustling around the house. When she suddenly stopped and shouted, blood was oozing from her nose. As kids, my siblings and I were terrified. We scrambled to help, but it wasn't until later that we learned the cause of that alarming moment: high blood pressure. That day was our first lesson in the silent yet powerful effects of hypertension. Nosebleeds, or epistaxis, are common, and nearly everyone experiences at least one in their lifetime.
While most are minor and often caused by dry air or irritation, some can signal underlying health concerns. One recurring question is whether high blood pressure causes nosebleeds or is merely coincidental.
The nose is covered by a rich plexus of small blood vessels, making it prone to bleeding. Most nosebleeds are anterior in origin, occurring at the front of the nose, and are relatively benign. They often occur because of irritants such as dry air, frequent nose-blowing, or trauma.
On the other hand, posterior nosebleeds are caused by a source that is located deeper within the nasal cavity. They are less common but more severe, as the blood tends to flow backward into the throat, making them more difficult to control. Common causes of posterior nosebleeds include trauma, medical conditions, or high blood pressure.
Hypertension is the condition whereby the pressure of blood against the arterial walls is consistently too high. Over time, this may damage the fine blood vessels in the nose, causing them to rupture more easily.
Significant studies have shown a strong relationship between hypertension and severe cases of nosebleeds necessitating urgent care. A certain study showed that patients diagnosed with high blood pressure had 2.7-fold increased chances of having nosebleeds that were not slight.
However, it should be noted that mild hypertension by itself does not cause nosebleeds. Nosebleeds are more likely to happen during a hypertensive crisis when the blood pressure suddenly rises to above 180/120. A hypertensive crisis can also have other symptoms such as a severe headache, shortness of breath, and anxiety. Therefore, it is considered a medical emergency.
Chronic hypertension makes the walls of blood vessels weaker and less elastic, which easily causes them to tear. In the nose, this is especially vulnerable because the blood vessels are close to the surface. Sudden surges in blood pressure, such as in a hypertensive crisis, can cause tears in these weakened vessels, resulting in nosebleeds.
While hypertension is a contributing cause, nosebleeds occur infrequently as the only manifestation of high blood pressure. This makes regular monitoring for blood pressure all the more crucial, as hypertension has the reputation of being the "silent killer" since people often do not present symptoms until the disease has run its course.
For most nosebleeds, you can manage them yourself at home:
1. Sit up and lean slightly forward to prevent swallowing blood.
2. Press your nostrils together for at least 10 minutes.
3. Use a cold compress on the bridge of your nose to constrict blood vessels.
4. If the bleeding continues, use a nasal decongestant spray.
Consult a doctor if the bleeding persists beyond 20 minutes, is heavy, or follows a head injury.
Preventive measures can decrease the incidence of nosebleeds:
For patients with hypertension, managing blood pressure is the best way to minimize the risk of complications. A combination of lifestyle changes, such as maintaining a healthy diet, regular exercise, and prescribed medications, can help keep blood pressure in check.
Most nosebleeds are harmless, but they can sometimes be signs of an underlying health condition. In adults with high blood pressure, frequent or severe nosebleeds should never be ignored. A health provider should be consulted in order to rule out any serious conditions and ensure appropriate treatment.
Regular check-ups, a healthy lifestyle, and awareness about the relationship between nosebleeds and high blood pressure would go a long way to protect your health. Indeed, prevention is always better than cure.
Epistaxis and hypertension. Post Graduate Medical Journal. 1977
Credits: Canva
A new, highly mutated COVID variant called 'Cicada' is spreading in the US. This is the BA.3.2 mutation of the COVID-19 variant. While nationally the cases of COVID have remained low, the BA.3.2 strain is gaining traction across the globe.
Cicada or the BA.3.2 strain emerged over a year ago, and simmered until last fall. However, this was when it started ramping up in countries including the US. As of February, BA.3.2 has been detected in at least 25 states, noted the US Centers for Disease Control and Prevention (CDC).
The variant's slew of genetic changes in its spike protein is what has made people concerned. This is what makes it unique and distinct from other variants in circulation.
According to Andrew Pekosz, Ph.D., a virologist at the Johns Hopkins Bloomberg School of Public Health, as reported by TODAY.com, "It [the variant] has a lot of mutations that may cause it to look different to your immune system."
The SARS-CoV-2 virus that causes COVID-19 mutates constantly and spreads over time. It thus leads to emergence of new variants.
A new study published in the CDC’s Morbidity and Mortality Weekly Report suggests that emerging variants could weaken protection gained from prior COVID-19 infection or vaccination.
One such “hyper-mutated” strain, BA.3.2, is now being closely tracked by public health officials. In December 2025, the World Health Organization classified it as a “variant under monitoring.”
Read: COVID Variant BA.3.2 Spreads To 23 Countries: Is The Variant Under Monitoring A Cause Of Worry?
BA.3.2 was first detected in South Africa in November 2024. It is a descendant of BA.3, an Omicron subvariant that appeared in 2022 and briefly circulated alongside BA.1 and BA.2, according to the CDC.
Although BA.3 never became dominant, it did not completely disappear. “It fizzled out, but persisted at low levels,” said Pekosz. After two years and dozens of mutations, BA.3.2 eventually emerged.
For much of 2024, the variant spread quietly, overshadowed by dominant strains like Nimbus and XFG, which stem from BA.2. However, by September, BA.3.2 began gaining ground. “It was under the radar, replicating, until it started spreading more efficiently between people,” Pekosz noted.
What sets BA.3.2 apart is its spike protein, which carries an unusually high number of mutations — around 70 to 75. This makes it significantly different from strains such as JN.1 and LP.8.1, which current COVID-19 vaccines are designed to target.
The CDC describes BA.3.2 as a “genetically distinct” lineage compared to recent variants. Early laboratory studies suggest it may be capable of evading existing immunity, as its spike protein changes help it escape neutralising antibodies.
The BA.3.2 variant is nicknamed by T Ryan Gregory, Ph.D., a professor of evolutionary biology at the University of Guelph. He wrote on X, formerly Twitter: "Well, it's that time again. Meet "Cicada", BA.3.2* (including descendant RE.*). This one has been underground for years (its ancestor BA.3 hasn't been circulating since early 2022, and didn't do much then either) but is now emerging as a contender for the next major lineage."
While most of the symptoms of this new variant remains same as from the other variants, one thing that stands out here is the gastrointestinal symptoms that cicada could cause. However, experts note that this variant will not make anyone more sicker. Other symptoms include:
Credits: iStock
On March 13, the Ministry of Social Justice and Empowerment introduced the Transgender Persons (Protection of Rights) Amendment Bill, 2026, in the Lok Sabha. Amid opposition, the Rajya Sabha gave its not to the Bill on March 25. The bill seeks to amend the Transgender Persons (Protection of Rights) Amendment Act 2019. The bill was passed in the Lok Sabha on March 24.
What the law originally promised: India's legal framework for transgenders rights comes from the landmark NALSA v. Union of India ruling. This is where the Supreme Court recognized transgender persons as 'third gender' and affirmed their fundamental rights, including access to healthcare. The 2019 amendment followed and promised non-discrimination in education employment, housing, and crucially, healthcare. As per a Live Law analysis, the law was intended to align with constitutional guarantees of equality and dignity, especially under Article 14 (Equality Before Law), 15 (Prohibition of Discrimination), and 21 (Right To Life).
Recent amendments have however raised concerns because of how it could reshape access to healthcare and recognition of identity.
The Bill introduces stricter verification of identification and tightens the definition of transgender identity by replacing self-identification with mandatory medical certification. This, many argue is against the 2019 Act supported by the NALSA judgment.
'We, the transgender people of India, reject the erasure of our identity," writes Dr Aqsa Shaikh for the media outlet - The Indian Express. One of the biggest concerns she and many pointed was the continued requirement of official certification for gender identity.
While the law does not always explicitly mandate surgery, activists argue that in practice, access to updated identity documents often becomes tied to medical procedures.
This creates barriers to gender-affirming healthcare, which includes hormone therapy, surgeries, and mental health support.
Dr Shaikh, who is a transgender professor at the Department of Community Medicine in Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, argues that such provisions undermine the principle of self-identification, which was central to the NALSA judgment.
Experts have long pointed out that transgender healthcare in India is already limited:
Critics also argue that the amendments do little to expand healthcare infrastructure, focusing instead on administrative control.
Health activists have also flagged the absence of:
This is significant because transgender individuals face disproportionately high rates of:
Without systemic healthcare guarantees, the law’s protections risk remaining symbolic.
An opinion piece in The Leaflet describes this bill as an "architecture of erasure". The piece argued that it weakens recognition of diverse transgender identities by reinforcing bureaucratic control. Dr Shaikh argues that the community rejects any framework that takes away the right to self-identify, calling it a rollback of constitutional morality.
Furthermore, a LiveMint report notes that the amendment is a "hurried, short-sighted decision" because it was passed without adequate consultation with transgender communities, it ignores lived experiences and healthcare needs, and prioritizes regulation over welfare.
Live Law notes that any law that govern transgender rights must remain consistent with the NALSA judgment. However, the recent amendment could dilute the principle supported by NALSA judgment that gender identity is based on self-perception and not state or medical approval.
Credits: Canva
Metformin Brain: A popular diabetes drug, prescribed to manage type 2 diabetes by controlling blood sugar, which has been in use for 60 years - metformin, now shows how it is directly linked to the brain.
A drug used for over six decades did not have a study that made scientists sure of exactly how it works, until now. Researchers from the Baylor College of Medicine in the US were able to identify in 2025 a brain pathway that the drug seems to work through. It also has impacts on biological processes in other areas of the body.
"It's been widely accepted that metformin lowers blood glucose primarily by reducing glucose output in the liver. Other studies have found that it acts through the gut," said Makoto Fukuda, a pathophysiologist at Baylor.
"It's been widely accepted that metformin lowers blood glucose primarily by reducing glucose output in the liver. Other studies have found that it acts through the gut," said Makoto Fukuda, a pathophysiologist at Baylor.
In a 2025 study on mice, researchers observed that metformin travels to the VMH and switches off Rap1 activity. This action appears to be crucial for its ability to control blood sugar. To test this further, scientists bred mice that lacked Rap1. In these mice, metformin no longer improved diabetes-like symptoms, even though other medications still worked.
This points to something important. Metformin may be working through a completely different pathway compared to other diabetes drugs, one that depends on the brain.
Read: Metformin Controls Blood Sugar With Help From Brain Neurons, Finds Study
The researchers also identified specific nerve cells involved in this process. They found that SF1 neurons become active when metformin enters the brain, suggesting these cells play a direct role in how the drug works.
These findings could change how doctors and scientists think about diabetes treatment. If metformin’s brain pathway is confirmed in humans, future therapies could be designed to target these exact neurons, making treatments more precise and possibly more effective.
There is also a bigger picture. Metformin has already been linked to benefits beyond diabetes, including slowing aspects of brain aging and improving longevity. In one study involving postmenopausal women, those taking metformin had a significantly lower risk of dying before the age of 90 compared to those on another diabetes drug.
Read: Metformin Can Help Lower Risk Of Age-related Vision Loss: Study
While the results are promising, human studies are still needed. If confirmed, this discovery could open the door to new treatments that not only manage blood sugar better but also tap into the brain’s role in overall health and aging.
It also reinforces an emerging idea that metformin is not just acting on the body’s metabolic organs, but quietly influencing the brain at much lower doses.
© 2024 Bennett, Coleman & Company Limited